𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Epirubicin plus low-dose trastuzumab in HER2 positive metastatic breast cancer

✍ Scribed by Alessandra Gennari; Michele De Tursi; Consiglia Carella; Enrico Ricevuto; Cinzia Orlandini; Antonio Frassoldati; Pierfranco Conte; Paolo Bruzzi; Stefano Iacobelli

Publisher
Springer US
Year
2008
Tongue
English
Weight
255 KB
Volume
115
Category
Article
ISSN
0167-6806

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Trastuzumab plus vinorelbine or taxane c
Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: The trastuzumab and vinorelbine or taxane study
✍ Harold J. Burstein; Aparna Keshaviah; Ari D. Baron; Ronald D. Hart; Rosemary Lam πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 157 KB

## Abstract ## BACKGROUND. The optimal trastuzumab‐based chemotherapy regimen for HER2‐overexpressing, metastatic breast cancer is not known. The __tr__astuzumab __a__nd __vi__norelbine __o__r __ta__xane (TRAVIOTA) study was a prospective, multicenter, randomized trial that was designed to compare